Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 13Neoplasm Metastasis 12Prostatic Neoplasms 9Neoplasms 7Glioblastoma 7Kidney Neoplasms 6Brain Neoplasms 6Sarcoma 5Carcinoma, Hepatocellular 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Glioma 4Endometrial Neoplasms 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Advanced Cancer 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Oligodendroglioma 3Multiple Myeloma 3Lymphoma, Mantle-Cell 3Liver Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2

Interventions

Iodine-131 14trametinib 9dabrafenib 9Thyroidectomy 9Surgical Procedures, Operative 9lenvatinib 8Thyroxine 8Magnetic Resonance Spectroscopy 8pembrolizumab 7Paclitaxel 7anlotinib 6Thyrotropin Alfa 6selpercatinib 5Sorafenib 5Saline Solution 5Radiofrequency Ablation 5Everolimus 5pazopanib 4Vemurafenib 4Sunitinib 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4Dexmedetomidine 4Cyclophosphamide 4Biopsy, Fine-Needle 4Biopsy 4Bevacizumab 4apatinib 3Triiodothyronine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Thyroid Neoplasms × temsirolimus × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT01025453 2018-08-15

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
37 enrolled 11 charts
Head & Neck

Thyroid Diseases, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡